Baird Upgrades Henry Schein to Outperform From Neutral, Adjusts Price Target to $92 From $81
Henry Schein Analyst Ratings
Morgan Stanley Adjusts Henry Schein's Price Target to $60 From $65
Henry Schein (HSIC) Gets a Sell From Morgan Stanley
Henry Schein Analyst Ratings
Henry Schein Analyst Ratings
Maintained OUTPERFORM Rating for Henry Schein Amidst Recovery and Growth Prospects
Henry Schein Analyst Ratings
Piper Sandler Reiterates Overweight on Henry Schein, Maintains $86 Price Target
Henry Schein Analyst Ratings
Barrington Research Maintains Outperform on Henry Schein, Raises Price Target to $92
UBS Adjusts Price Target on Henry Schein to $80 From $82, Maintains Neutral Rating
Henry Schein Analyst Ratings
UBS Maintains Neutral on Henry Schein, Lowers Price Target to $80
Analysts Have Conflicting Sentiments on These Healthcare Companies: Henry Schein (HSIC) and Esperion (ESPR)
Barrington Ups Price Target on Henry Schein to $92 From $90, Maintains Outperform Rating
Goldman Sachs Adjusts Price Target on Henry Schein to $74 From $76
Baird Adjusts Price Target on Henry Schein to $81 From $83, Maintains Neutral Rating
Henry Schein Sell Rating Affirmed Amidst Cybersecurity Woes and Execution Risks
Henry Schein: Strong Q1 Earnings but Uncertain Outlook Warrants Hold Rating